NCT01908101 - Eribulin Mesylate in Treating Patients With Previously Treated Metastatic Breast Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 8, 2014

Primary Completion Date

May 4, 2019

Study Completion Date

May 4, 2019

Conditions

Recurrent Breast CarcinomaStage IV Breast Cancer

Interventions

DRUG

Eribulin Mesylate

Given IV

OTHER

Laboratory Biomarker Analysis

Correlative studies

Trial Locations (12)

59715

Bozeman Deaconess Hospital, Bozeman

85724

The University of Arizona Medical Center-University Campus, Tucson

97701

Bend Memorial Clinic, Bend

98109

Fred Hutch/University of Washington Cancer Consortium, Seattle

98112

Group Health Cooperative-Seattle, Seattle

98274

Skagit Valley Hospital, Mount Vernon

98362

Olympic Medical Center, Port Angeles

98405

MultiCare Tacoma General Hospital, Tacoma

98801

Wenatchee Valley Hospital and Clinics, Wenatchee

99336

Kadlec Clinic Hematology and Oncology, Kennewick

99508

Katmai Oncology Group, Anchorage

Providence Alaska Medical Center, Anchorage

All Listed Sponsors

collaborator

National Cancer Institute (NCI)

NIH

lead

University of Washington

OTHER